Arginine vasopressin release in response to the administration of 3,4-methylenedioxymethamphetamine (“ecstasy”): is metabolism a contributory factor?
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The aim of this investigation was to examine the effect of 3,4-methylenedioxymethamphetamine (MDMA) administration on arginine vasopressin (AVP) release. (R,S)-MDMA (40 mg) was administered to eight normally hydrated healthy male volunteers (22–32 years) and blood samples were collected up to 24 h. Plasma was assayed for AVP and cortisol by radioimmunoassays, and for MDMA and the N-demethylated metabolite, MDA, by gas chromatography-mass spectrometry. Sodium concentrations and osmolality were also determined. Plasma AVP increased in all subjects after MDMA administration and a significant negative correlation was observed between concentrations of AVP and both single and total enantiomer MDMA at 1 h (r < −0.91, P < 0.01). This had disappeared by 2 h (P > 0.7). Compared with basal values, no significant change was observed for osmolality or cortisol at 1 h after drug administration. In conclusion, plasma AVP concentrations increase after MDMA administration, but the increase is not part of a generalized stress response since cortisol did not increase concurrently. A significant negative correlation between plasma MDMA and AVP was observed soon after administration. The possibility that a pharmacological effect of MDMA is primarily mediated via one or more metabolites, rather than by the parent drug, should be considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fabian, M., Forsling, M. L., Jones, J. J., & Pryor, J. S. (1969) · The Journal of Physiology · doi:10.1113/jphysiol.1969.sp008937 · Cited by 107 · cited 1×
“Given the difference in clearance rates between MDMA (Fallon et al 1999) and AVP (Fabian et al 1969), together with the possible diminishing responsiveness of the magnocellular neurones during the study, one would only expect to see any clear relationship soon after drug administration.”
Self-citationDaily patterns of secretion of neurohypophysial hormones in man: effect of age
Forsling, M., Montgomery, H., Halpin, D., Windle, R., & Treacher, D. (1998) · Experimental Physiology · doi:10.1113/expphysiol.1998.sp004124 · Cited by 93 · cited 2×
“An increase in AVP secretion would not be expected at this time of day (Forsling et al 1998).”
MethodSelf-citationMILSOM, S. R., DONALD, R. A., ESPINER, E. A., NICHOLLS, M. G., & LIVESEY, J. H. (1986) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1986.tb01688.x · Cited by 31 · cited 1×
“The response to noradrenaline is also unclear in man, the earliest reports suggested no effect (Milsom et al 1986).”
Background
Cited by
The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”)
Green, A. R., Mechan, A. O., Elliott, J. M., O’Shea, E., & Colado, M. I. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.3.3 · Cited by 1,272
Designer drugs: mechanism of action and adverse effects
Luethi, D., & Liechti, M. E. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02693-7 · Cited by 262
A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers
Dumont, G. J. H., & Verkes, R. J. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106063271 · Cited by 149
Dolder, P. C., Müller, F., Schmid, Y., Borgwardt, S. J., & Liechti, M. E. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4650-5 · Cited by 117
Wolff, K., Tsapakis, E. M., Winstock, A. R., Hartley, D., Holt, D., Forsling, M. L., & Aitchison, K. J. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106061514 · Cited by 108
Self-citation
Metadata
- Authors
- Forsling, M., Fallon, J. K., Kicman, A. T., Hutt, A. J., Cowan, D. A., & Henry, J. A.
- Venue
- Journal of Pharmacy and Pharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-10-01
- Volume
- 53
- Issue
- 10
- Pages
- 1357-1363
- ISSN
- 0022-3573 (ISSN-L)
- 2042-7158
- OpenAlex
- W2147977831
- Cited by
- 49
- References
- 3
- FWCI
- 4.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.